Business
BioSpectrum Asia
Leadgene Biosolutions expands product portfolio for metabolic research
Leadgene Biosolutions has announced the expansion of its product portfolio following its strategic integration into Leadgene Biomedical.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Korea, Philippines to develop nextgeneration tuberculosis diagnosis
The Korea National Institute of Health (NIH), under the Korea Disease Control and Prevention Agency (KDCA) is entering into a research agreement with the Research Institute for Tropical Medicine (RITM) of the Philippines to initiate an international collaborative research project aimed at developing next-generation tuberculosis (TB) diagnostic technologies.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Australia and Indonesia achieve WHO Listed Authority status in medical products regulation
The World Health Organization (WHO) has formally recognised the regulatory authorities for medical products of Australia and Indonesia as WHO Listed Authorities (WLAs), an achievement that underscores growing global confidence in regulatory systems across diverse regions and income settings.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries
Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Aevice Health announces expansion into Australian market
AeviceMD Monitoring System, a non-invasive wearable respiratory monitoring solution developed by Singapore-based Aevice Health, has been included in the Australian Register of Therapeutic Goods (ARTG) as a Class IIa medical device.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Insilico Medicine lists on Hong Kong Stock Exchange, exhibiting largest Hong Kong biotech IPO
Insilico Medicine, a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange, becoming the first AI-driven biotech company to go public in Main Board under Chapter 8.05 listing rules of the HKEX.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Australia provides cheaper medicines for inflammatory & rare liver disease and MS
Australians living with a range of debilitating conditions including juvenile arthritis, rare liver disease and multiple sclerosis (MS) will pay less for newly Pharmaceutical Benefits Scheme (PBS) listed medicines, as directed by the Australian Government.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Valneva and Serum Institute of India discontinue Chikungunya vaccine license agreement
France-based Valneva SE, a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company, have mutually agreed to discontinue their license agreement for Valneva's single-shot chikungunya vaccine.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Santhera licenses AGAMREE to Nxera Pharma in $205 M Asia-Pacific deal
Swiss firm Santhera Pharmaceuticals has signed an exclusive licensing agreement with Nxera Pharma UK for the development, manufacturing and commercialisation of AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in Japan, South Korea, Australia and New Zealand.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
AdCella and Shanghai Cell Therapy Group launch global collaboration for cancer therapy
Australia-based AdAlta, developer of next generation cell and protein therapeutic products, and its cellular immunotherapy subsidiary, AdCella have signed a major development agreement with Shanghai Cell Therapy Group (SHcell) to bring an innovative cancer treatment, BZDS1901, to markets outside China.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
JNCASR and CrisprBits to set up CRISPR Centre of Excellence in Innovation and Translation
A Letter of Intent (LOI) has been signed for the establishment of CRISPR Centre of Excellence for Innovation & Translation (CoE-CIT).
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Hyphens Pharma outlicences Cerapro MED to 6 European countries
Singapore-based Hyphens Pharma International has granted the rights to commercialise its innovative product, Cerapro MED Skin Barrier Cream, to Louis Widmer SA via a licensing, supply and commercialisation agreement that covers six European countries, namely Switzerland, Liechtenstein, Austria, Belgium, Luxembourg and the Netherlands.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Fujifilm completes setting up of one of Japan's largest Bio CDMO facilities at Toyama
Fujifilm Corporation has announced the completion of one of Japan's largest bio CDMO facilities (the new plant) at the Toyama Second Factory of Fujifilm Toyama Chemical.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Gene Solutions and Pangea Laboratory establish strategic collaboration for cancer diagnostics
Vietnam headquartered startup Gene Solutions, & US-based Pangea Laboratory, a CLIAcertified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed Tests (LDTs), have announced a strategic collaboration to advance US verification & clinical validation of liquid biopsy assays designed for cancer detection, profiling, & monitoring.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Rakuten Medical and Lotte Biologics ink agreement to support biopharma in oncology
US-based Rakuten Medical, Inc. and South Korea's Lotte Biologics have signed a biopharmaceutical contract manufacturing agreement to strengthen Rakuten Medical's production capabilities for its innovative oncology therapy, Alluminox platformbased photoimmunotherapy.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Retinal Gene Therapy secures regulatory approval in Japan
Nanoscope Therapeutics, Inc., a biotechnology company developing disease-agnostic therapies for vision loss caused by retinal degeneration, has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted both Sakigake (Pioneering Regenerative Medical Product) and Orphan Drug designations to MCO-010, its lead optogenetic therapy for patients with severe vision loss from inherited retinal dystrophies (IRDS).
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Foresee Pharma inks $584.5 M deal with Primevera Therapeutics
Taiwan-based Foresee Pharmaceuticals has announced that Foresee Pharmaceuticals USA Inc., the company's fullyowned US subsidiary, has officially signed an exclusive global licensing agreement with Primevera Therapeutics, LLC for its MMP-12 inhibitor programmes.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
ElpasBio and Fosun Kairos collaborate to commercialise Allo Join stem cell therapy
China-based startup Elpas Bio Holdings has entered into a collaboration agreement with Fosun Kairos for the commercialisation of ElpasBio's investigational allogeneic human adipose-derived mesenchymal stem cell (haMPC) therapy, lotazadromcel (trade name AlloJoin) for the treatment of knee osteoarthritis (KOA) in Mainland China, Hong Kong SAR, and Macau SAR.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Biocon concludes Rs 4,150 Cr equity fundraise through Qualified Institutions Placement
Bengaluru-based Biocon has announced the successful completion of a Qualified Institutions Placement (QIP), raising Rs 4,150 crore ($460 million) through the issuance of 112,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per Equity Share (including a premium of Rs 363.35 per Equity Share).
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Hong Kong launches Chinese medicine hospital
A launch ceremony was recently held for the Chinese Medicine Hospital of Hong Kong (CMHHK) and the Government Chinese Medicines Testing Institute (GCMTI).
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
The Race to Build Singapore's Biotech Unicorns
MIRXES, known for its work in early cancer detection and backed by A*STAR and the National University of Singapore, became Southeast Asia's first biotech unicorn when it listed on the Hong Kong Exchange in 2025.
5 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
BIRAC inks Letter of Intent with Global Antibiotic Research & Development Partnership
Biotechnology Industry Research Assistance Council (BIRAC), under the Department of Biotechnology (DBT), Government of India, has announced a Letter of Intent (LOI) with the Global Antibiotic Research & Development Partnership (GARDP), a Swiss not-forprofit organisation that develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Sky Labs secures European approval for ring-type blood pressure monitor
South Korea based startup Sky Labs has announced that its ring-type blood pressure monitor 'CART PLATFORM,' recently obtained the European Union's Medical Device Regulation (CE-MDR) certification.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
AstraZeneca buys remaining China CAR-T therapy rights from AbelZeta Pharma for $630 M
US-based AbelZeta Pharma, Inc., a global clinicalstage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, has announced that AstraZeneca has agreed to acquire AbelZeta's 50 per cent share of the China development and commercialisation rights to C-CARO31, such that AstraZeneca acquires the sole right to develop, manufacture and commercialise C-CAR031 globally.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
"Neuroinflammation is not only a hallmark of Alzheimer's disease but a key pathological feature in other neurodegenerative disorders"
As dementia becomes the leading cause of death in Australia and Alzheimer’s disease continues to affect millions worldwide, the urgency for fundamentally new treatment strategies has never been clearer.
4 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
LivsMed completes largest KOSDAQ IPO of 2025, raising w135.9 B
LivsMed, a minimally invasive surgical device company, has completed an initial public offering on Korea’s KOSDAQ market, raising about $94 million ( ₩135.9 billion) at ₩55,000 per share.
1 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Leprosy Isn't Over: South-East Asia's Unfinished Fight
As we commemorate World Leprosy Day on January 25, the global community is oldest diseases-has not yet been consigned to history.
2 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
"Absence of a widespread infectious disease emergency in 2025 has hindered progress in combating AMR"
After decades of incremental antibiotic innovation, antimicrobial resistance (AMR) is outpacing our ability to respond, and 2026 may mark a breaking point.
5 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
The Strategic Rise of India's Deep-Science Economy
India is emerging as a powerful hub for deep science and biotechnology, driven by favourable geopolitics, a large domestic market, strong pharmaceutical and chemicals infrastructure, and supportive government policies.
4 min |
BioSpectrum Asia Feb 2026
BioSpectrum Asia
Japan strengthening biopharma capabilities
Asia's biopharma landscape is shifting rapidly toward innovation, with countries such as South Korea, Singapore, India, and Taiwan advancing R&D capabilities.
7 min |